Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $260,000
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- —
- Debt to equity
- —
Trading
- Volume
- 23,200
- Avg volume
- —
- Day's range
- $0.07 – $0.07
- Shares out
- —
- Stochastic %K
- 65%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.
- Phone
- 972 3 756 4999
- Website
- https://silexion.com
- Address
- 12 Abba Hillel Road, Ramat Gan, Israel
Latest news
No headlines yet.
